The addition of pembrolizumab to chemoradiotherapy improved survival outcomes for women with high-risk, locally advanced ...

The CRPC trial – KEYNOTE-921 – looked at the combination of Keytruda (pembrolizumab) with docetaxel in more than 1,000 patients who had not been treated with chemotherapy before, but who had ...

The conversion from accelerated approval to traditional approval was supported by data from the phase 3 KEYNOTE-811 trial.

The FDA has approved Keytruda plus chemotherapy in HER2+ gastric or GEJ adenocarcinoma with PD-L1–positive expression, based on KEYNOTE-811 data.

This exploratory genomic analysis of data from the KEYNOTE-059, KEYNOTE-061, and KEYNOTE-062 clinical trials represents a comprehensive evaluation of the clinical and molecular characteristics of late ...

While this pembrolizumab-based regimen is promising and much needed in this patient population, one should remain cognizant of its high costs and the subsequent impact this may have on patients and ...

Retrospective Analysis of BRCA-Altered Uterine Sarcoma Treated With Poly(ADP-ribose) Polymerase Inhibitors Using pretreatment tumor samples, bulk DNA was analyzed via ...